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Abstract: Serotonin (5-HT) is a critical player in brain development and neuropsychiatric disorders.
Fetal 5-HT levels can be influenced by several gestational factors, such as maternal genotype, diet,
stress, medication, and immune activation. In this review, addressing both human and animal
studies, we discuss how these gestational factors affect placental and fetal brain 5-HT levels, leading
to changes in brain structure and function and behavior. We conclude that gestational factors are
able to interact and thereby amplify or counteract each other’s impact on the fetal 5-HT-ergic system.
We, therefore, argue that beyond the understanding of how single gestational factors affect 5-HT-ergic
brain development and behavior in offspring, it is critical to elucidate the consequences of interacting
factors. Moreover, we describe how each gestational factor is able to alter the 5-HT-ergic influence on
the thalamocortical- and prefrontal-limbic circuitry and the hypothalamo-pituitary-adrenocortical-axis.
These alterations have been associated with risks to develop attention deficit hyperactivity disorder,
autism spectrum disorders, depression, and/or anxiety. Consequently, the manipulation of gestational
factors may be used to combat pregnancy-related risks for neuropsychiatric disorders.
Keywords: gestation; serotonin; neurodevelopment; neural circuit formation; neuropsychiatric disorders
1. Introduction
The neurotransmitter serotonin (5-HT) plays a major role in neuropsychiatric disorders and is
a key player in brain development [1,2]. In adulthood, 5-HT cannot cross the blood–brain barrier,
while its precursors tryptophan and 5-hydroxytryptophan (5-HTP) can (see review [3]). However,
roughly during the first half of pregnancy, 5-HT can be transferred from the mother’s placenta, via
the fetal periphery, to the fetal brain [4–6]. It is, therefore, likely that the maternal environment can
greatly influence fetal brain development. This, in turn, may play a role in the onset of multiple
neuropsychiatric disorders, as many of these disorders seem to have a developmental origin [7].
Further insight into how gestational factors can influence the fetal 5-HT system may advance our
understanding of the aetiology underlying several neuropsychiatric disorders.
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1.1. The 5-HT System and Its Embryonic Development
As illustrated in Figure 1, 5-HT signaling is tightly controlled by (1) tryptophan hydroxylase (TPH),
the rate-limiting enzyme of 5-HT synthesis, and by (2) the 5-HT transporter (5-HTT), which is responsible
for the high-affinity reuptake of 5-HT. Two TPH isoforms have been identified to synthesize 5-HT from
tryptophan. TPH1 is responsible for 5-HT synthesis in the periphery and to a smaller extent also in the
brain pineal gland. TPH2 is essential for 5-HT synthesis in the brain [8,9]. In addition, TPH2 is also
important for 5-HT synthesis in the enteric nervous system and thereby the regulation of gastrointestinal
motility [10]. In the brain, 5-HT is synthesized by 5-HT-ergic neurons located in the various nuclei of
the raphe nuclei in the brainstem and is transported into synaptic vesicles by the vesicular monoamine
transporter isoform 2. The exocytosis of these vesicles releases 5-HT into the synaptic cleft, where it binds
to post-synaptic 5-HT receptors. Thus far, at least 14 different 5-HT receptor subtypes have been identified
(5-HT1A/B/D/E/F, 5-HT2A/B/C, 5-HT3, 5-HT4, 5-HT5A/B, 5-HT6, and 5-HT7), which can trigger a variety of
signaling cascades. All but the 5-HT3 receptor are metobotropic and belong to the G protein-coupled
receptor superfamily. A complete overview of the receptor’s transduction mechanisms is beyond the scope
of this review and has been discussed in detail previously [11,12]. Of note, at the cost of 5-HT, tryptophan
can also serve as a precursor of kynurenine via the rate-limiting enzymes tryptophan 2,3-dioxygenase (TDO)
and indoleamine 2,3-dioxygenase (IDO) [13]. Kynurenine is further degraded into multiple neuroactive
metabolites, including kynurenic acid and quinolinic acid. The kynurenine pathway plays a role in immune
response and inflammation [14,15].
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Figure 1. An integrated view of 5-HT signaling within the brain. 5-HT in the brain is synthesized
from tryptophan via the enzymes Tph2 and AADC. 5-HT is transported via VMAT into synaptic
vesicles. Exocytosis of these vesicles releases 5-HT i to the synaptic cleft. Here, it can bind t 5-HT
receptors localized on pre- and postsynaptic neurons and/or on glial cells (microglia, astrocytes, and
oligodendrocytes). 5-HT signaling can be terminated by the reuptake of 5-HT via the 5-HT transporter.
5-HT is again transported into synaptic vesicles or converted to 5-HIAA via the enzyme MAOA. Within
neurons, microglia, and astrocytes, tryptophan can be converted into kynurenine via the enzymes
IDO and TDO. 5-HIAA: 5-hydroxyindole amino acid; 5-HT: serotonin; AADC: aromatic L-amino acid
decarboxylase; IDO: indoleamine 2,3-dioxygenase; MAOA: monoamine oxidase A; TDO: tryptophan
2,3-dioxygenase; TPH2: tryptophan hydroxylase 2; VMAT: vesicular monoamine transporter.
The various developmental stages of the fetal 5-HT system are largely comparable between
humans and rodents. In humans, 5-HT-ergic neurons are first evident in the hindbrain at gestational
week 5 [16] after which they project to the forebrain, reaching the cerebral cortex around gestational
week 10 and the most rostral telencephalon around gestational week 13 [17]. At gestational week
15, during the second trimester of human pregnancy, the typical organization of clustered 5-HT cell
bodies into the raphe nuclei is observed [18]. Similarly, in rodents, 5-HT-positive cells are observed
in the raphe nuclei around embryonic day (E) 10–12, which corresponds to the second trimester of
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pregnancy in humans. One day after their appearance, these cells are able to synthesize 5-HT [2].
5-HT-ergic axons reach the forebrain in mice around E16.5 and in rats around E17.5 [19,20]. Interestingly,
5-HT-ergic signaling molecules are already present in the forebrain before 5-HT-ergic axons reach
it. Human data show the expression of 5-HTT in the brain around gestational week 8, i.e., the first
trimester of pregnancy [21]. Similarly, in mice and rats, brain 5-HTT is detected around E8-9 in the
forebrain [2,22–24]. This suggests that an exogenous source may provide the fetal forebrain with 5-HT
before the actual 5-HT-ergic projections reach the forebrain.
1.2. Maternal and Placental Sources of 5-HT
Two exogenous sources have been reported to supply the fetus with 5-HT: the placenta and
maternal platelets, i.e., 5-HT overflow from the gut. Although these two sources are clearly associated
with the fetal 5-HT supply, it is still quite unclear what the varying degrees of supply from the placenta
and maternal platelets are and whether they act in parallel [25]. Two studies reported that the placenta
expresses both maternal and fetal isoforms of TPH1 and TPH2 (mouse placenta [19] and human
placenta [26]), whereas another study was not able to detect placental TPH1 (mouse and human
placentas [25]). It is, therefore, not fully clear as to whether the placenta has the necessary machinery to
synthesize 5-HT from maternal tryptophan. Other literature suggests that maternal platelets serve as
the exogenous source for the delivery of 5-HT to the fetus [5,25]. Maternal platelets degranulate in the
intervillous space of the placenta, thereby releasing maternal 5-HT into the placenta. Subsequently, this
maternal 5-HT is transferred through the placenta to the fetus. This transfer is facilitated by, among
others, the fetal isoform of 5-HTT and organic cation transporter 3 (OCT3) [25]. However, Bonnin and
colleagues could not find support for the hypothesis that maternal platelets serve as the exogenous
source of 5-HT to the fetus. That is, 5-HT levels in the forebrain of 5-HTT heterozygotic embryos from
5-HTT knockout dams did not differ from those of 5-HTT heterozygotic embryos from 5-HTT wildtype
dams [19]. It should be mentioned that the placenta does express monoamine oxidase A (MAOA), an
enzyme responsible for 5-HT breakdown [27]. Hence, this enzyme may influence placental 5-HT levels
and thus control the regulation of fetal 5-HT. Despite the unclarities, the placenta-derived 5-HT content
(referring to both placenta and platelet 5-HT supply) is expected to play vital roles in the regulation
of fetal processes. This exogeneous source is mainly provided to the fetus throughout the first half
of the pregnancy, which is around the same time as 5-HT-regulated developmental events including
corticogenesis and circuitry maturation occur [2]. For this reason, gestational factors affecting not
only an offspring’s raphe-produced 5-HT content but also placenta-derived 5-HT content can have
substantial effects on an offspring’s early brain development.
1.3. Aim of Review
We performed an extensive literature search up to February 2020 using the PubMed database. The
key characteristics of referred human and animal studies are shown in Table S1 and S2, respectively. The
objective of this review is to carry out a comprehensive approach towards gestational factors affecting the
fetal 5-HT system and as a result may affect an offspring’s brain development and behavior regarding
neuropsychiatric disorders. We first introduce this topic by providing background information concerning
5-HT-ergic neuromodulatory effects on brain development (Section 2). Thereafter, we highlight what
is currently known about the effects of gestational factors on an offspring’s brain 5-HT system and
neuropsychiatric disorders related to brain development and behavior (Section 3). Gestational factors
include maternal 5-HT-ergic genotype, 5-HT-related diet composition, stress, 5-HT-related medication,
and immune activation. Finally, we discuss the (interactive) impact of the gestational factors on the
placenta-derived and offspring’s raphe-produced 5-HT content, the related brain circuit development,
and how these effects may provide risk of the onset of specific neuropsychiatric phenotypes later in life
(Section 4). Noteworthy paternal and postnatal environmental factors, such as paternal genotype and
maternal care, may influence an offspring’s 5-HT system and development as well. These factors have
been discussed in detail previously (e.g., [28]) and are beyond the scope of this review.
Int. J. Mol. Sci. 2020, 21, 5850 4 of 41
2. Modulatory Effects of 5-HT on Brain Development
During development, 5-HT in the brain is involved in a variety of neurodevelopmental processes,
such as neuronal proliferation and migration, as well as initial axon targeting and circuitry maturation [2].
Of note, 5-HTT and the vesicular monoamine transporter are transiently expressed on forebrain
glutamatergic neurons [2,29]. This expression is observed before raphe nuclei-derived 5-HT-ergic
projections are born until the second week of postnatal life [29]. Glutamatergic neurons in the
forebrain are located in various cortical structures that play a role in complex behavior including the
sensory cortex, prefrontal cortex (PFC), and hippocampus [2,30]. Furthermore, glutamatergic neurons
project from the thalamus to the cortex (i.e., thalamocortical afferents). 5-HT accumulation in these
glutamatergic neurons modulates responsiveness of neurons to guidance cues, and 5-HT may function
itself as a guidance cue as well [31,32].
5-HT receptors within the brain are expressed on neurons as well as glial cells. As shown in
Table 1, activation of neuronal 5-HT receptors is involved in the above-mentioned neurodevelopmental
events (for more details see Sections 2.1 and 2.2). Activation of astrocytic 5-HT receptors have
been reported to play a role in neurogenesis and the release of the neurite-extending growth factor
S100β (see review [11]). Interestingly, 5-HT regulates astrocytic activity, a cell type that has an
important role in modulating synaptic function and network activity within a variety of brain areas
including the PFC [33]. The microglial-expressed 5-HT2B receptor regulates 5-HT neurotransmission
by releasing nitric oxide, cytokines, and glutamate, which, in turn, affect 5-HTT-mediated 5-HT
clearance [34]. Moreover, microglia play an important role in brain maturation and inflammation.
They are involved in cell positioning and survival and in synaptic patterning within various cortical
structures including the sensory cortex, PFC, and hippocampus [35]. Regarding oligodendrocytes,
elevated extracellular 5-HT levels negatively affect 5-HT2A-dependent oligodendrocytes’ survival (i.e.,
aberrant outgrowth, increased development-dependent cell death) leading to reduced myelination [36].
The recent investigations regarding the function of 5-HT and 5-HT receptors in the different glial cells
are exciting and might result in refreshing new insights into the role of 5-HT in the development of
these brain cells. Thus far, most studies have investigated the role of 5-HT on neuronal development.
Table 1. 5-HT receptor involvement in neurodevelopmental events.
Neurodevelopmental Events 5-HT Receptors Involved
Cell proliferation and survival/apoptosis
Postsynaptic 5-HT1A/B/D & 2A & 6
Astrocytic 5-HT1-7
Microglial 5-HT2B/7
Neuronal migration/positioning Postsynaptic 5-HT1A/B/D & 3 & 6Microglial 5-HT2B/7
Neuronal activity Postsynaptic 5-HT1A & 2A/CAstrocytic 5-HT1-7
Neuronal outgrowth/dendrite formation Postsynaptic 5-HT1A & 2A & 3 & 4 & 6 & 7
Neuronal connectivity Presynaptic 5-HT2AOligodendrocyte 5-HT2A
Synaptic formation/function Astrocytic 5-HT1-7
Synaptic clustering Presynaptic 5-HT1BPostsynaptic 5-HT1D
Synaptic patterning Microglial 5-HT2B & 7
5-HT neurotransmission
(i.e., 5-HT clearance and release)
Presynaptic 5-HT1A/B & 5A
Microglial 5-HT2B & 7
HPA-axis activation Postsynaptic 5-HT1A & 2A/2C
5-HT: serotonin; HPA: hypothalamo-pituitary-adrenocortical.
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2.1. Corticogenesis and Circuit Maturation
During embryonic development, 5-HT projections to the forebrain regulate certain aspects of
corticogenesis, including neuronal migration and the proper positioning of pyramidal neurons and
interneurons [2,37–39]. It has been shown that 5-HT-ergic fibers within cortical regions, including the
medial PFC (mPFC), contact Cajal Retzius cells, and thereby possibly affect reelin release [40–42]. In
turn, reelin affects the correct placement of pyramidal neurons in cortical layers [43]. How exactly 5-HT
affects migration of pyramidal cells is still unclear. Another course of action via which the 5-HT system
can influence neuronal migration involves the 5-HT receptors. The 5-HT6 receptor has been shown
to mediate pyramidal neuron migration via controlling the activity of CDK5/p35, a master regulator
of pyramidal neuron migration [44]. Interneuron migrational events are mediated through both the
5-HT6 and 5-HT3 receptors [39,44–47]. More specifically, activation of the 5-HT3 receptor increases
calcium currents into the cell, thereby promoting the migratory speed of cortical interneurons during
the invasion of the cortical plate. The modulation of calcium transients is speculated to be through the
regulation of N-methyl-D-aspartate receptors, also known as the NMDA receptors, and voltage-gated
calcium channels [45,46].
5-HT also affects several other aspects of circuitry maturation, such as neurite outgrowth, pruning,
and the remodeling of dendritic spines [48–51]. For example, activation of 5-HT receptors enhances
neurite outgrowth and leads to neuronal survival [52,53]. The influence of 5-HT in neurite outgrowth
is furthermore studied using a Pet-1 knockout animal model. Pet-1 is a key transcriptional regulator
that controls 5-HT neuronal levels: depletion of this regulator results in a 70% reduction of raphe
5-HT neurons and an 80% reduction of forebrain 5-HT levels due to a diminished cortical innervation
by 5-HT projections [54]. Such diminished 5-HT-ergic innervation leads to alterations in cortical
interneuron activity as well as cortical neuron identity and placement and may result in an increase in
cortical network excitability [55]. Pet-1 knockout mice also show elevated sensitivity to 5-HT1 and
5-HT2 receptors, resulting in spontaneous synaptic activity [56].
2.2. Brain Circuits’ Structure and Function
Due to 5-HT’s role in neurodevelopmental events, changes in 5-HT levels can impact the maturation
and the functioning of a variety of brain circuits, including thalamocortical and prefrontal-limbic
circuits, as well as the hypothalamo-pituitary-adrenocortical (HPA)-axis. As described below, these
circuits play an important role in the aetiology of neuropsychiatric disorders.
The thalamocortical projections mediate somatosensory (tactile) perceptions. Areas involved
are the thalamus, the primary somatosensory barrel cortex, and the secondary somatosensory cortex.
5-HT accumulation in thalamocortical afferents plays a critical role in the formation of sensory
cortices. Primary somatosensory barrel cortex development is greatly dependent on extracellular
5-HT concentrations regulated by the transient 5-HTT and 5-HT1B receptor expression on these
thalamocortical afferents [32,57]. Activation of the 5-HT1B receptor has been shown to negatively
regulate presynaptic glutamate release [58]. In turn, this negative regulation can instruct the clustering
of postsynaptic excitatory synapses in the typical barrel formation [59]. Presynaptic 5-HT2A receptors,
which are located at thalamocortical synapses throughout life, additionally control the NMDA-operated
induction of thalamofrontal connectivity and the associated cognitive functions [60]. Moreover,
somatosensory cortical inhibition, and, in turn, sensory processing, is affected by 5-HT-regulated
astrocytic purinergic signaling [61]. Alterations in 5-HT levels can thus lead to structural and functional
reorganization of thalamocortical afferents as well as intracortical microcircuitry. Altered development
of sensory cortices will result in changes in the perception of sensory stimuli early in life. It has been
shown that alterations in this circuitry can contribute to the development of pathologies, such as autism
spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and depression [62,63].
Another circuitry influenced by alterations in 5-HT levels is the prefrontal-limbic circuitry. This
circuitry plays a crucial role in stress and emotional responses [64]. Areas include the mPFC, basal
ganglia, amygdala, and hippocampus. 5-HT plays a prominent role in this circuitry as multiple
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receptors (e.g., 5-HT1A and 5-HT2A) are expressed in these areas [65]. In the mPFC, these receptors
are mainly involved in modulating cortical activity. Whereas 5-HT1A receptors inhibit pyramidal
neurons and interneurons via activation of GIRK channels, the 5-HT2A receptors excite these neurons
via unknown mechanisms [66]. Indeed, drug-induced alterations in 5-HT2A receptor activity influence
attention and impulsive behavior (see review [66]). This circuitry is often involved in the onset of
various neuropsychiatric disorders, such as ASD, ADHD, anxiety, and depression [67,68].
The HPA-axis is yet another circuitry whose development can be influenced by alterations in
5-HT levels. It is a crucial neuroendocrine signaling system involved in physiological homeostasis
and the adrenal glucocorticoid stress response [69]. The HPA-axis involves the hypothalamus
where corticotrophin releasing factor is being produced, the pituitary that responds to corticotrophin
releasing factor to produce the hormone adrenocorticotropin, and the adrenal cortex that responds
to adrenocorticotropin to produce cortisol (in humans) or corticosterone (in rodents). Activation of
this axis occurs via a discrete set of neurons in the hypothalamic paraventricular nucleus. These
neurons are influenced by indirect input from limbic system-associated regions, including the mPFC,
hippocampus, and amygdala. Accumulating data suggest a regulation of the corticotrophin releasing
factor neuronal activity and thus activation of the HPA-axis via 5-HT1A and 5-HT2A receptors at the
hypothalamus and via 5-HT2C receptors at the hypothalamic paraventricular nucleus [70,71]. A change
in 5-HT levels results in altered 5-HT-ergic innervations in the hypothalamic paraventricular nucleus
and the hippocampus [72] and thereby can severely affect basal HPA-axis activity, predominantly at the
level of the adrenal gland [73]. This, in turn, can lead to severe hormonal imbalances. Dysregulation
of the HPA-axis is strongly implicated in the pathology of mood disorders, such as depression and
anxiety disorders [74–76].
3. Gestational Factors Influence Fetal Development during the Embryonic Period and after Birth
3.1. 5-HT-ergic Maternal Genotype Influences the 5-HT System, Neurodevelopment, and Behavior in the Offspring
As proposed previously by Gleason and colleagues, maternal genetic variations affecting the 5-HT
system (hereafter called maternal 5-HT-ergic genotype) are able to influence fetal development [77].
Changes in the 5-HT system can occur through alterations in placental and fetal 5-HT levels or through
transmission of risk alleles. The effects of the transmission of risk alleles on an offspring’s brain
development and behavior are discussed in other reviews (e.g., [21]). In short, maternal 5-HT-ergic
genotype perturbs fetal 5-HT homeostasis by increasing or decreasing 5-HT supply. The animal studies
addressed below suggest that the thalamocortical circuitry is particularly sensitive to maternal variance
in 5-HT-ergic genotype.
3.1.1. Associations with Behavioral Changes in Offspring in Humans
A variety of human studies link maternal 5-HT-ergic genotype to differences in an offspring’s
brain structure and function, as well as behavior. A well-known and common polymorphic variant
is the 5-HT transporter-linked polymorphic region (5-HTTLPR). This polymorphism consists of two
variants, the short (S)-allelic and long (L)-allelic variant. The S-allelic variant confers reduced 5-HTT
gene transcription, thereby reducing 5-HTT’s availability in cultured human lymphoblast cells and
in the brain as measured via single photon emission computed tomography [78,79]. In one study,
children heterozygous for 5-HTTLPR were divided into two groups depending on maternal 5-HTTLPR
genotype, thus either S/S or L/L. Children from mothers homozygotic for the S allele were found to
lift their pencils less often in a visuomotor performance task in comparison to children from mothers
homozygotic for the L allele. This finding correlated with changes in their somatosensory cortex
grey matter density. That is, children with denser grey matter lifted their pencils less often [80].
Interestingly, regarding associated neuropsychiatric disorders, children of 5-HTTLPR L-allele carrying
mothers have a higher risk of ASD [81], while no association was found between 5-HTTLPR allelic
variants and the occurrence of depression in mother–child groups [82]. Lower levels of maternal
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whole-blood 5-HT levels measured at mid-pregnancy were associated with the most severely affected
ASD phenotypes [83]. The offspring of mothers carrying TPH1 loss-of-function mutations exhibited
1.5- to 2.5-times higher ADHD scores in comparison to controls and the offspring from fathers carrying
such mutations [84]. Future studies with whole genome sequencing between mother and child and
the neurobehavioral development of the child could potentially yield a guidance to whether which
genotype combination exactly has an increased risk of the development of neuropsychiatric disorders.
3.1.2. 5-HT System Alterations in the Animal Offspring
To follow up on the human data, a variety of animal studies have linked maternal 5-HT-ergic
genotype to structural and functional alterations in the offspring. For example, studies reported that
maternal 5-HT1A receptor deficiency is associated with reduced juvenile ultrasonic vocalizations, adult
anxiety-like traits in the offspring, increased stress responsiveness, and delayed development of the
ventral dentate gyrus, independent of an offspring’s genotype [85,86]. Furthermore, mouse fetuses,
capable of producing their own 5-HT but conceived by a TPH1 knockout mother (i.e., lacking 5-HT
in the periphery), showed a reduced mitotic activity within the roof of the neocortex (future cerebral
cortex) together with dramatic abnormalities in the shape of this region and of hindbrain regions [5].
In support, E18 TPH1 knockout embryos from TPH1 knockout dams showed also a decrease in
proliferation rate in comparison to TPH1 wildtype embryos from TPH1 wildtype dams [87]. Another
way to investigate maternal 5-HT-ergic genotype effects is the use of the 5-HTT Ala56 gain-of-function
mutation mouse model [88]. In general, 5-HTT Ala56 mice display increased CNS 5-HT clearance,
enhanced 5-HT receptor sensitivity, elevated peripheral blood 5-HT levels, and increased ASD-like
behavior [89]. Offspring from Ala56 mothers displayed decreased placental and embryonic forebrain
5-HT levels and a broadening of 5-HT-sensitive somatosensory thalamocortical afferents at E14.5. The
forebrain 5-HT homeostasis recovered at E18.5 [6], when 5-HT raphe fibers had reached the forebrain.
3.2. Maternal 5-HT-ergic-Related Diets Influence the Tryptophan Pathway, Neurodevelopment, and Behavior in
the Offspring
Another route via which the mother can influence her offspring’s development involves her
diet. Nutrients received from the mother via the placenta or during lactation are crucial for an
offspring’s health and growth [90,91]. In the following sections, we describe the effects of maternal
tryptophan-related diets, high-fat diets, and alcohol consumption on 5-HT-ergic brain development of
the offspring. In short, depending on the composition of the diet, the mother can perturb fetal 5-HT
homeostasis by increasing or decreasing fetal 5-HT availability and influencing the fetal 5-HT system
in the hippocampus, hypothalamus, amygdala, the raphe nuclei, and the mPFC.
3.2.1. Maternal Tryptophan-Related Diets Affect the Placental Tryptophan Pathway in Animals
The most obvious nutritional component that can affect 5-HT-ergic development in the offspring
is tryptophan, the essential amino acid that serves as the precursor of 5-HT. Tryptophan is amongst
others found in salmon, poultry, eggs, spinach, seeds, milk, soy products, and nuts. The greatest part of
the consumed tryptophan is directly metabolized in the liver, the rest binds to albumin and circulates
freely throughout the body [92]. Tryptophan supplements can be consumed to increase tryptophan
availability and enhance 5-HT synthesis. Already in 1991, it was shown that oral administration of
tryptophan during gestation in rodents increased fetal whole brain tryptophan and 5-HT levels [93].
A diet enriched with tryptophan (i.e., 50 g/kg) resulted in increased maternal, placental, and fetal
tryptophan levels. As a result, both placental development and fetal growth were reduced, and pup
death rate increased [94]. Less enriched tryptophan diets (i.e., ±10 g/kg) also resulted in peripheral
hyperserotonemia and increased TPH activity in the gastrointestinal tract of dams and their pups [95–97].
However, opposed effects in the offspring’s brain (in contrast to the gastrointestinal tract) were reported
due to low tryptophan enriched diets (i.e., ±10 g/kg). Namely, decreased frontal cortex 5-HT levels
and TPH activity were found, probably caused by a delay in 5-HT axon outgrowth [96]. Remarkably,
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chronic deprivation of tryptophan (in contrast to enriched tryptophan diets) also resulted in decrements
of dorsal raphe 5-HT-ergic neuron populations and neuronal migration disturbances, leading to an
altered topography of the raphe nucleus (i.e., rostralization instead of caudalization of the dorsal
raphe nucleus) [98]. Consequently, tryptophan-deprived diets resulted in decreased 5-HT levels in
the PFC and decreased hippocampal but increased striatal 5-HT metabolism in adult offspring [99].
Such a diet deprived of tryptophan also resulted in a decrease in striatal brain derived neurotrofic
factor (BDNF) levels and a reduction in hippocampal proliferation rate and in neuronal outgrowth, i.e.,
reduced dendritic spine density and abnormal dendrite swelling [99,100]. Notably, active maternal
care seems to be reduced by a tryptophan-deprived diet and thus may aggravate the above described
effects [99]. Depressive-like behavior in the offspring has also been reported upon neonatal tryptophan
deprivation [99], which may be due to either a reduction in maternal care, disturbed brain maturation,
or their interaction.
To ensure the transport of tryptophan from the mother to the fetus, a diet high in carbohydrates
and low in proteins has been suggested [101]. Carbohydrates evoke insulin secretion. Insulin, in
turn, reduces most large amino acids, with the exception of tryptophan [102]. In humans and rodents,
the transfer of placental tryptophan from maternal blood into the fetal circulation is predominantly
mediated by the so-called system A and system L transporters [103,104]. System A functions in a
sodium-dependent manner to mediate the uptake of nonessential amino acids into the cell. In this
way, a gradient is created that is used to drive the exchange for extracellular essential amino acids,
such as tryptophan, via sodium-dependent system L [105]. Excessive amounts of nonessential amino
acids in the maternal blood thus might increase the maternal-fetal transfer of essential amino acids,
including tryptophan. Multiple animal studies investigated the effects of gestational low-protein
diets on an offspring’s brain 5-HT system. Notably, some studies used isocaloric protein diets in
which the low protein diets were adjusted with a higher content of carbohydrates, thereby creating
low-protein high-carbohydrate diets. Such low-protein high-carbohydrate diets reduced maternal
plasma tryptophan levels and increased maternal plasma 5-HT levels and the offspring’s brain 5-HT
levels after birth [106,107]. It remains unclear whether the exposure to such diets decreases or
increases placental and fetal 5-HT levels [106,107]. When using a low-protein high-carbohydrate diet
supplemented with tryptophan, neither the maternal nor fetal 5-HT system is altered [108]. Importantly,
when exposed to a prenatal carbohydrate-restricted diet consisting of similar protein levels, and thus
tryptophan levels, as the control diet, fetal whole brain concentrations of tryptophan, 5-HT, 5-HIAA
were reduced [109].
With regard to lasting effects within specific brain regions in the offspring, (isocaloric) maternal
low-protein diets, irrespective of the gestational period, resulted in increased 5-HT levels in the mPFC,
hypothalamus, and hippocampus throughout life [106,110–112]. However, a few studies were not able
to replicate adult hypothalamic and hippocampal 5-HT increments [107,113–115]. Not only offspring’s
5-HT levels but also 5-HT-ergic receptors are influenced due to gestational exposure to low-protein
diets. A prenatal isocaloric low-protein diet resulted in a reduced expression of the hypothalamic
5-HT2C receptor at birth and throughout life [107]. Similarly, a reduced hippocampal 5-HT1A receptor
functionality has been reported [113,116]. Interestingly, Ye and colleagues recently reported that
the reduced 5-HT1A receptor functionality was accompanied by an increased sensitivity to stress
throughout life [116].
3.2.2. Maternal High-Fat Diet Reduces 5-HT Production in the Animal Offspring
Maternal high-fat diets throughout pregnancy result in an increased susceptibility to developing
ASD, ADHD, anxiety, and depression. Potential mechanisms underlying offspring behavioral changes
include maternal increases in nutrients (glucose and fatty acids) and hormones (insulin and leptin),
maternal and placental increases in oxidative stress, and inflammatory cytokines. In turn, these
maternal dysregulations increase the risk of placental dysfunction, as well as an increased inflammation
in the fetal brain, alterations in the dopaminergic, and 5-HT-ergic systems in the fetal brain and
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perturbations in synaptic plasticity and the HPA-axis (see reviews [117–120]). Indeed, a perinatal
high-fat diet in primates revealed an increase in fetal dorsal raphe nucleus TPH2 gene expression,
and after birth, decrements in 5-HT levels in the cerebrospinal fluid, a reduction in TPH2 mRNA
expression in the dorsal and median raphe nuclei, and an upregulation of the 5-HT1A receptor in
the dorsal raphe nucleus. Interestingly, these effects were associated with increases in anxiety-like
behavior in juvenile primates [121,122]. In rodents, similar findings were obtained, since pregestational
together with perinatal high-fat diet resulted in an increase in dorsal hippocampal BDNF and ventral
hippocampal 5-HT1A gene expression and in anxiety-like behavior in adult offspring. Although, the
offspring conditioned fear response and exploratory behavior were not affected [123].
3.2.3. Maternal Alcohol Consumption Reduces Fetal 5-HT Production
Moderate to severe maternal alcohol consumption throughout pregnancy is associated with a
disrupted brain development, attention deficits, hyperactivity, and impulsiveness in the offspring (see
review [124]). Prenatal alcohol consumption is potentially linked to decreased 5-HT levels in maternal
human serum and reduced 5-HTT binding in children’s medial frontal cortex [125,126]. Similarly,
decreased rodent fetal whole brain 5-HT levels were reported, irrespective of the number of days
exposed to alcohol [127–129]. The maternal alcohol-induced reduction in fetal 5-HT levels probably
occurs due to reduced 5-HT-ergic neurons and TPH-positive cells within the raphe nuclei of the
offspring [130–134]. These reductions have been linked to a lower expression of several pro-survival
genes (i.e., the NF-κB-dependent anti-apoptotic genes: XIAP, cIAP1, cIAP2, Bcl-2, and Bcl-xl) and an
increase in apoptotic cell death in the rat hindbrain [135,136]. Indeed, the migration and differentiation
of 5-HT neurons towards their final position within the raphe nucleus was found to be diminished in
the offspring by prenatal alcohol exposure [134]. Interestingly, such distortion in 5-HT-ergic neurons
in the raphe nuclei could be prevented by maternal treatment with a 5-HT2A/2C receptor agonist or a
5-HT1A receptor agonist [127,133,136,137]. More specifically, the 5-HT1A agonist, ipsapirone, which
likely acts on somatodendritic 5-HT1A receptors on both raphe neurons and astrocytes. Through
agonistic activations of these cell types, ipsapirone prevented the reduction in expression of the
pro-survival genes XIAP and Bcl-xl. Hence, these pro-survival genes might provide a mechanism
into how ethanol-induced apoptosis can be protected via ipsapirone. [133,136]. Behaviorally, maternal
alcohol-induced decrements in raphe 5-HT-ergic neurons resulted in a decreased susceptibility of and
resistance to anxiety [131].
In rodents, maternal alcohol consumption not only results in alterations in 5-HT-ergic neurons,
but also in 5-HT-ergic fibers from the raphe nuclei. More specifically, fewer 5-HT fibers were observed
in E15- and E18-fetal’s brain in a variety of brain areas including the hypothalamus, hippocampus,
and frontal and parietal cortices, and a reduction in the growth of the 5-HT-regulated somatosensory
thalamocortical projections was observed [138]. Underdevelopment of the thalamocortical projections
is thought to be the underlying cause of the volume reduction seen in the posterior medial barrel
subfield (especially layer IV) and of the reduced numbers of neurons in this area. These alterations
have been suggested to lead to compromised sensory modality [139]. Moreover, the 5-HTT gene
expression and binding of the HPA-axis and prefrontal-limbic circuitry also seem to be sensitive to
dysregulation evoked by prenatal alcohol exposure [140].
3.3. Maternal Stress Affects the 5-HT System, Neurodevelopment, and Behavior in the Offspring
Maternal stress (defined as physical and/or psychosocial stress during pregnancy) can negatively
influence child health and a variety of pediatric aberrations have extensively been reported (for
review [141]). The effects of maternal stress on the maternal HPA-axis resulting in excessive fetal
cortisol levels has been most extensively described in literature. In recent reviews, the effects of
maternal stress on the placental and fetal 5-HT systems is briefly discussed as potential underlying
factor as well. These 5-HT alterations may affect fetal brain development and increase the risk of
the onset of neuropsychiatric disorders, such as ASD, depression, and anxiety [141–143]. In the
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following sections, we will review human and animal studies describing the effects of maternal stress
on 5-HT-related brain development and function in the offspring. In animals, stressors used include
electric foot shocks, restraint under bright light, auditory stimuli, cold water immersion, forced swim,
wet bedding, crowding, saline injection, and cage rotation. Some studies use one of these stressors
to mimic maternal stress, while others make use of chronic unpredictable stress models whereby, in
general, animals are exposed to up to two of these stressors daily. In short, maternal stress is associated
with both increases and decreases in 5-HT levels in the offspring. Increases in 5-HT levels affect
development of the thalamocortical circuitry, whereas decreases in 5-HT levels affect development of
the prefrontal-limbic circuitry. The HPA-axis is affected in almost all maternal stress models, irrelevant
of the offspring’s 5-HT level changes.
3.3.1. The Role of Prenatal Stress in Offspring Brain Development in Humans
Human studies clearly show that prenatal stress affects neurodevelopment including functional
and structural brain connectivity alterations involving the amygdala and frontal cortex and changes
in the HPA-axis functionality. In turn, these alterations induce long-lasting effects on children’s
mental health (see review [144]). Studies concerning the role of maternal and fetal 5-HT levels in
relation to stress, however, are scarce. Rotem-Kohavi and colleagues investigated neonatal brain
function organization of children exposed to either maternal depression (indicative of maternal stress)
only or selective serotonin re-uptake inhibitors (SSRIs) and maternal depression. Neonates from the
depressed-only group showed higher hub values (hubs are highly connected brain regions) in the
left anterior cingulate, insula, caudate, and amygdala. Hub values of these regions in neonates of
SSRI-depressed mothers did not differ from neonates of healthy mothers. These findings may suggest
that SSRIs normalize the depression-induced alterations during brain development [145]. Consequently,
both maternal depression and prenatal SSRI-exposure might have overlapping underlying mechanisms,
which potentially involves the fetal 5-HT system. Indeed, high maternal anxiety, depression, and anger
scores during and after pregnancy decreased neonatal peripheral 5-HT levels together with greater
relative right frontal EEG activation, altered sleep patterns, and lower motor organization. However,
no difference in maternal peripheral 5-HT levels were found during and after pregnancy [146].
3.3.2. Prenatal Stress Alters the 5-HT System in the Animal Offspring
During the embryonic period, maternal stress increases fetal brain 5-HT levels. An early study
reported that chronic mild psychosocial prenatal stress increased maternal plasma tryptophan levels
and increased levels of tryptophan, 5-HT, and 5-HIAA in fetal whole brain and neonatal cortex [147].
Maternal stress induced via either pregestational or prenatal chronic unpredictable stress led to increased
forebrain, hippocampal, and hypothalamic 5-HT levels, decreased 5-HTT expression in both brain
areas, and decreased hippocampal 5-HT1A receptor activity in the fetus [148,149]. However, animal
studies have reported conflicting data regarding maternal stress-induced lasting effects on offspring’s
5-HT levels. Researchers found decreases in brain 5-HT levels of adolescent and adult offspring when
using different maternal stress models. Upon maternal stress, hypothalamic, hippocampal, and mPFC
5-HT levels were reduced and PFC 5-HT metabolism was increased [150–155]. TPH2 gene and protein
levels were decreased in the dorsal raphe nucleus, and the hippocampus and 5-HTT protein levels were
increased in hippocampal and PFC brain regions [154,156]. Another group of researchers showed data
in favor of maternal stress-induced increases in adult offspring 5-HT levels in similar brain regions and
using similar maternal stress models. Maternal stress resulted in a decreased hippocampal 5-HTT and
alterations in the dorsal raphe, i.e., increases in 5-HT levels and TPH2 gene expression and enhanced
TPH2 immunoreactivities [157,158]. Of note, another study showed prenatal restraint stress-induced
decreases in 5-HT-positive cell density and overall 5-HT immunoreactivity in the dorsal raphe nucleus
of adult animals but increases in overall immunoreactivity in the mPFC and increased hippocampal
TPH2 immunoreactivity. No difference was found in TPH2 immunoreactivity in either the dorsal
raphe nucleus or the mPFC [159].
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3.3.3. Prenatal Stress-Induced Alterations in Brain Circuits and Behavior in the Animal Offspring
The above-mentioned studies show not only alterations in offspring’s 5-HT levels in response to
maternal stress but also imply neurodevelopmental changes. Prenatal chronic unpredictable stress
not only increased embryonic forebrain 5-HT levels but also increased 5-HT+ fetal thalamic neurons
and thalamocortical afferents [149]. Studies showing a decrease in an offspring’s 5-HT levels in
response to maternal stress suggest alterations within the prefrontal limbic circuitry. Pregestational
and prenatal stress reduced hippocampal neurogenesis and reduced synaptic plasticity (synaptophysin
and PSD-95 densities) in the mPFC and hippocampus of adolescent rats [150,151,155,160]. Moreover,
prenatal chronic unpredictable stress caused hippocampal structural modifications (decreases in
ventral hippocampal sub-region volume together with a decrease in number of neurons; increases in
dorsal hippocampal sub-region volume) [153]. Research supporting maternal stress-induced increases
as well as decreases in an offspring’s brain 5-HT levels have suggested a maternal stress-induced
over-activated HPA-axis in the offspring. Different maternal stress models increased fetal and adult
offspring plasma and serum (baseline and stress-induced) corticosterone levels, corticotrophin releasing
factor, and the hormone adrenocorticotropic and increased amygdala corticotrophin releasing factor
gene expression [148,153,154,158,159]. Furthermore, diminished hippocampal glucocorticoid receptor
levels and density were detected [158,160]. Of note, maternal stress-induced fetal changes in serum
corticosterone and corticotrophin releasing factor have been suggested to cause the discussed 5-HT-ergic
modifications. Whilst such changes in corticosterone in adulthood are proposedly caused by long-term
changes in HPA function in response to the altered 5-HT-regulated cortical releasing factor neuronal
activity [148].
Not only brain morphology but also behavior of the offspring is affected by maternal stress. Many
studies show maternal stress-induced increases in offspring’s anxiety and depressive-like behavior,
irrespective of the applied maternal stress model and 5-HT levels measured in the offspring [153,
154,156–159,161–163]. Consistently, animals exposed to prenatal stress did not develop any form of
stress adaptation [164]. However, in a few other studies prenatal stress did not affect or even decrease
depressive- and anxiety-like behaviors [162,165]. Proposed mechanisms underlying these anxiety- and
depressive-like behaviors are an increased HPA-axis reactivity, decreased transcriptional regulation
factors CREB and BDNF in the prefrontal-limbic circuitry, and increases in placental inflammation and
placental IGFBP-1 expression. Increases in this gene expression causes a decrease in available growth
factors [153,154,158,161]. No clear association was found with hyperactivity or impulsivity, which
are putative indicators for ADHD. Most studies did not find any effect, however one study reported
hyperactive adult mice and two other studies reported hypo-locomotion [153,154,157,158,161,162,165].
Prenatal restraint stress and pregestational chronic unpredictable stress, respectively, decreasing and
increasing offspring’s 5-HT metabolism, reduced social behavior in juvenile and adult offspring.
Mechanisms underlying these behavior alterations probably include the above discussed reduced
hippocampal plasticity and over-activated HPA-axis function [150,152,160]. Reduced social behavior
has been suggested to be a potential indicative for the development of ASD-like behaviors [152].
3.4. Maternal Intake of 5-HT-ergic Medication Alters 5-HT Levels in Offspring and Affects Their
Neurodevelopment and Behavior
Pregnant women suffering from depression, migraine, or schizophrenia are sometimes in need
of medication during pregnancy. Medication is taken during 6% of all pregnancies [166]. Over the
years, multiple reviews have been written trying to disentangle the effects attributable to prenatal SSRI
exposure from the underlying maternal disorder and the maternal-child transmission of risk alleles
to neuropsychiatric disorders. Due to inconsistent study results, review outcomes differ. There is a
tendency, however, towards viewing SSRI exposure as a plasticity rather than a risk factor [167–173].
This means that SSRI exposure can positively or negatively influence offspring’s 5-HT system depending
on other gestational factors. In the following sections, we describe the effects of maternal intake of 5-HT
receptor (ant)agonists and SSRIs during pregnancy on offspring’s 5-HT-ergic brain development and
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neuropsychiatric disorders-related behaviors, referring to both human and animal studies. In short,
there is quite some overlap between human and animal findings. Maternal SSRI intake alters fetal
5-HT levels; however, the direction remains unclear. Nevertheless, these fetal brain 5-HT alterations
could explain the remarkable changes in fetal brain development related to the thalamocortical and
prefrontal-limbic circuits, as well as the HPA-axis that we address in this review.
3.4.1. Maternal Intake of 5-HT Receptor (Ant)Agonist Might Affect the Unborn Child
Triptans are 5-HT1B/1D receptor agonists, which are often prescribed as medication against migraine
and cluster headaches. Triptans cross the placenta [174] and, thus, may bind to these receptors in
the fetal brain. Indeed, a clinical study showed an increased risk of attention problems in children
prenatally exposed to triptans (particularly when exposed during the first trimester of pregnancy) [175].
Furthermore, antipsychotic medications, such as clozapine, have a high affinity as an antagonist/inverse
agonist for (placental) 5-HT1A and 5-HT2A receptors [176,177]. Therefore, clozapine might be able to
influence the placental or fetal 5-HT system and thus fetal neurodevelopment.
3.4.2. Maternal SSRI Intake is Associated with Neural Changes and Behavior in Offspring in Humans
In many countries, provided guidelines prefer the use of psychotherapy and other
non-pharmaceutical treatments as first-line treatments against mild to moderate depression during
pregnancy. Antidepressants such as SSRIs are only preferred in severe cases of depression.
However, current practice shows that most of the time antidepressants are still used as the primary
treatment [178–180]. The effect of SSRIs during pregnancy on an offspring’s development has been
examined frequently. Indications of a reduced brain maturation and neural development are the
decrease in reelin and S100β found in infants of mothers exposed to SSRIs during pregnancy [181,182].
The programming of the HPA-axis seems to be altered as well, as reflected by increased serum
corticosteroid binding globulin levels (even when controlling for maternal depression) and decreases in
cortisol reactivity [183,184]. In support, Brennan et al. [184] suggested a moderate role for psychotropic
medication (mainly SSRIs) in the relationship between maternal disorders during pregnancy and
infant cortisol levels. Due to such changes, altered brain morphology is expected. Indeed, infants
prenatally exposed to SSRIs have increased volumes of, and connectivity between, the amygdala and
insular cortex [185]. Children prenatally exposed to SSRIs further displayed an increase in connectivity
in the right medial frontal orbital gyrus [145]. Moreover, a recent study revealed that newborns
prenatally exposed to SSRIs exhibited white matter changes in the basal ganglia and thalamus [186].
These white matter changes suggest that SSRI exposure affects axon myelination as well. As shown in
Table 2, most human case-control and cohort studies have found an association between SSRI intake
of the pregnant mother and risk of neuropsychiatric disorders (for more details see Table S1). In
general, studies consider the maternal neuropsychiatric condition as an important confounding factor.
Interestingly, even though the association with offspring depression decreased, the association stayed
significant when comparing SSRI-depressed mothers with depressed-only mothers instead with healthy
controls [187,188]. As to whether prenatal SSRI exposure evokes a risk of ASD development is unclear.
Positive associations between prenatal SSRI exposure and ASD are mainly found in meta-analyses
focusing on case-control studies and on early gestational exposure (pre-gestation and first trimester).
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Table 2. Literature overview of associations between human maternal SSRI intake and child alterations.
In depth information about the key characteristics of each article can be found in Table S1. We
included meta-analyses but also case-control and cohort studies that were not included in one of
the meta-analyses.
Increased Risk of Association Found
Association Not Found or Mainly
Caused by the Underlying
Maternal Psychiatric Condition
ADHD -
Man et al. [189] (meta-analysis)
Sujan et al. [190]
Uguz [191] (systematic review)
Anxiety/Depression
Hermansen et al. [192]
Lupattelli et al. [187]
Malm et al. [188]
-
ASD
Andalib et al. [193] (meta-analysis)
Brown et al. [194] (meta-analysis)
Fatima et al. [195] (review)
Gentile [196] (review)
Kaplan et al. [197] (meta-analysis)
Man et al. [198] (meta-analysis)
Mezzacappa et al. [199] (meta-analysis)
Brown et al. [200]
Kaplan et al. [201] (meta-analysis)
Kobayashi et al. [202]
(meta-analysis)
Sujan et al. [190]
ADHD: attention deficit hyperactivity disorder; ASD: autism spectrum disorders.
3.4.3. Maternal SSRI Intake Affects Animal Offspring 5-HT Signaling and Behavior
Numerous developmental consequences of gestational SSRI exposure (i.e., prenatal, neonatal, or
perinatal) have also been reported in animal studies. These investigations mainly used healthy animals.
To translate animal findings to the clinic, it is imperative to study gestational SSRI exposure not only
in healthy animals but also in combination with maternal stress during pregnancy. As discussed
below, gestational SSRI exposure seems to be able to mitigate some of the developmental effects of
prenatal stress. It is, however, also able to alter developmental mechanisms and behaviors without
counteracting prenatal stress; similar to the human study of Rotem-Kohave et al. [145]. That both
gestational SSRI exposure and prenatal stress can influence brain development independent of each
other is also highlighted in another review focusing specifically on hippocampal plasticity [203].
Animal models reported behavioral changes that partly correspond to those found in human
studies (Table 3 & Table S2). Like in humans, rodents gestationally exposed to SSRIs do not seem to
show increases in hyperactivity or impulsivity. As in human studies, several, but not all, studies do
show an increase in anxiety- and depression-like behavior due to gestational SSRI exposure. There is
no clear reason why studies using fluoxetine during a similar period and of similar concentrations
evoke different depressive-like outcomes across studies. Different outcomes might be related to the
specific SSRI, SSRI concentration, or behavioral test used. For instance, studies that tested citalopram
or used the novelty suppressed feeding test (a test suggested to detect behaviors related to anxiety as
well as depression [204]), mostly suggest an increased anxiety-like behavior. Studies using the highest
fluoxetine concentrations resulted in decreased anxiety levels. Studies without significant differences
mainly used the elevated plus maze as behavioral test (a test supposedly primarily detecting anxiety
levels [204]) and low fluoxetine concentrations. Regarding ASD, rodent studies often investigate
alterations in the sensory system, repetitive behavior, and social behavior (including social preference,
social play, and social interaction). Gestational SSRI-exposed offspring mostly show an impaired social
preference and social play behavior. Inconsistencies concerning social play and social interaction
outcomes are probably due to environmental differences, i.e., semi-natural environment versus familiar
versus unfamiliar playmates and juvenile versus adolescent versus adulthood. An earlier review of
Gemmel et al. [151] suggested that the timing of gestational SSRI exposure might explain differences in
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social behavior. However, this is not visible when looking at the current available literature (Table 3).
Nonetheless, overall, ASD-related behavior seems to be affected by SSRIs.
Table 3. Literature overview of associations between perinatal SSRI exposure in rodents and behavioral
changes in the offspring. In depth information about the key characteristics of each article can be found
in Table S2. Specifications are added when the SSRI effects were studied in gestational stressed animals.
Abnormalities Association Found Association Not Found
Hyperactivity & impulsivity -
Khatri et al. [205]
Ko et al. [206]
Lisboa et al. [207]
McAllister et al. [208]
Olivier et al. [209]
Increased depressive-like
behavior
Lisboa et al. [207]
Ko et al. [206]
Popa et al. [210]
Rayen et al. [162] (normalised stress
effect)
Rebello et al. [7]
Sprowles et al. [211]
Zohar et al. [163] (irrespective of
stress effect)
Altieri et al. [212]
Gobinath et al. [213]
McAllister et al. [208]
Olivier et al. [209]
Salari et al. [161] (normalised stress
effect)
Increased anxiety-like behavior
Altieri et al. [212]
Ansorge et al. [214]
Ansorge et al. [215]
Gobinath et al. [213]
Khatri et al. [205]
Olivier et al. [209]
Rebello et al. [7]
Smit-Rigter et al. [216]
Sprowles et al. [211]
Zohar et al. [163] (irrespective of
stress effect)
Altieri et al. [212]
Bairy et al. [217]
Ehrlich et al. [218]
Harris et al. [219]
Kiryanova et al. [165] (irrespective
of stress effect)
Kiryanova & Dyck [220]
Ko et al. [206]
Lisboa et al. [207]
McAllister et al. [208]
Meyer et al. [221]
Popa et al. [210]
Salari et al. [161] (normalised stress
effect)
Silva et al. [222]
Yu et al. [223]
Zimmerberg & Germeyan [224]
Repetitive behavior and sensory
abnormalities
Lee [225]
Ko et al. [206]
Maloney et al. [226]
Sprowles et al. [211]
McAllister et al. [208]
Decreased social behavior
Bond et al. [227]
Maloney et al. [226] (social
preference)
Ehrlich et al. [218]
Khatri et al. [205]
Olivier et al. [209]
Rodriguez-Porcel et al. [228]
Simpson et al. [229]
Silva et al. [222]
Yu et al. [223]
Zimmerberg & Germeyan [224]
Houwing et al. [230]
Gemmel et al. [150] (normalised
stress effect)
Gemmel et al. [160] (irrespective of
stress effect)
Ko et al. [206]
Maloney et al. [226] (social
interaction)
Meyer et al. [221]
Svirsky et al. [231]
Zaidan et al. [232]
A few studies investigated the effects of gestational SSRI exposure on the 5-HT system of the
offspring. Offspring of pregnant mice that were perinatally treated with fluoxetine and sertraline
or prenatally with escitalopram exhibited whole brain decreases in MAOA expression and whole
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brain increases in cortical expression of TPH2, 5-HTT, and 5-HT1A/2A/C receptors [218,221,227]. These
molecular changes likely lead to increased 5-HT signaling. However, other studies showed a
reduction in brain 5-HT levels in the offspring. More specifically, perinatal fluoxetine resulted in
decreased juvenile whole-brain 5-HT levels [165,220]. Neonatal escitalopram exposure led to decreased
adult hippocampal 5-HT levels along with reduced 5-HTT binding in the median and dorsal raphe
nucleus [212]. Notably, neonatal fluoxetine did not alter adult 5-HT levels in the mPFC, hippocampus,
and somatosensory cortex [206,212]. Contradicting findings are also seen in studies investigating
the effects of gestational SSRI exposure on prenatally stress exposed offspring. Prenatal citalopram
exposure has been reported to normalize prenatal chronic unpredictable stress-induced increases
in fetal forebrain 5-HT levels [149]. Neonatal fluoxetine exposure to prenatally restraint stressed
offspring decreased hippocampal 5-HT levels [233]. Gestational SSRI intake also normalized maternal
stress-induced decreases in an offspring’s 5-HT level. For instance, pre-adolescent offspring from
dams pregestationally exposed to chronic unpredictable stress and perinatally treated with fluoxetine,
reported that fluoxetine treatment normalized the diminished 5-HT levels and 5-HT metabolism in the
PFC and the hippocampus [150,151].
3.4.4. Maternal SSRI Intake Affects Animal Offspring’s Brain Circuitry Development
Changes in offspring’s 5-HT system may result in altered functioning of specific brain circuits.
One of the circuits that is mainly affected in the offspring from neonatal SSRI exposed healthy dams is
the thalamocortical circuitry. Alterations within this circuitry are associated with the above discussed
sensory abnormalities and decreased social behavior [206,225,229]. Fluoxetine exposure led to a
reduction in the complexity of thalamocortical afferents projecting to layer four of the barrel cortex (i.e.,
fewer/shorter branches) [225]. Further, paroxetine exposure was associated with altered refinement,
but not the formation, of dense clusters of these afferents (i.e., reduced barrel size and enlarged
septa) [234]. Neonatal citalopram exposure suppressed the amplitude and prolonged the delay of
sensory-evoked potentials, reduced the power and frequency of the early gamma oscillations, and
suppressed sensory evoked and spontaneous neuronal firing in the barrel cortex of neonatal rats.
These effects were absent during adolescence, indicating that the changes were transient [235]. Finally,
retrograde tracer studies in neonatal fluoxetine exposed rats revealed a change in the morphology of
oligodendrocytes in the corpus callosum. This change was associated with altered axon myelination in
the corpus callosum and reduced connectivity between the primary somatosensory cortices across the
hemispheres [229]. Interestingly, prenatal citalopram intake was found to decrease p11 expression in
fetal thalamic neurons. The authors suggest that this decrease in p11 expression alters 5-HT signaling
through regulating the translocation and signaling of 5-HT1B/D receptors, thereby potentially disturbing
thalamocortical circuitry formation [236]. This might explain how prenatal citalopram exposure
decreases and, therefore, normalizes the increased 5-HT-containing thalamocortical afferents evident
in prenatal stressed fetus [149]. Thus, while neonatal SSRI exposure in healthy animals negatively
influence thalamocortical circuitry development, these alterations seem to normalize the gestational
stress-induced effects.
The HPA-axis is a brain circuitry, which is mainly affected by gestational SSRI intake studied
in the offspring from stressed dams. Alterations have been related to the earlier discussed increases
in anxiety-like behavior (probably via increased 5-HT2C receptor gene expression in the PFC and
amygdala) and enhanced social preference [213,232]. While prenatal fluoxetine in healthy dams
reduced stress-induced plasma corticosterone levels in adult male offspring, neonatal fluoxetine in
healthy dams increased these levels in the serum of adult male offspring. In both studies, basal
corticosterone levels were unaffected [213,222]. Consistently, when studying perinatal fluoxetine
in prenatal restraint stressed offspring, fluoxetine normalized prenatal stress-induced increases in
HPA-axis reactivity in adulthood. This time, however, perinatal fluoxetine also decreased baseline
serum corticosterone levels [161]. Such a decrease in plasma basal corticosterone levels was also found
in adolescent male rats after neonatal fluoxetine exposure. This time, however, prenatal restraint stress
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did not affect these levels [237]. That perinatal SSRI exposure, irrespective of prenatal stress, can
impact the HPA-axis has been shown in other studies as well. Perinatal fluoxetine resulted in increased
serum corticosteroid binding globulin, decreased hippocampal synaptic protein (PSD-95), reduced
glucocorticoid receptor density in the hippocampus, and reduced glucocorticoid receptor density in
the mPFC [150,160,203,237].
Another brain circuitry affected by gestational SSRI exposure in both healthy and prenatally
stressed animal models is the prefrontal-limbic circuitry. A few studies suggest a link between
presynaptic 5-HT1A activity and social interaction or depressive-like behavior and between hippocampal
neurogenesis and anxiety-like behavior [210,213,218]. Other studies propose the decrease in mPFC
dendritic complexity as one of the underlying mechanisms in decreased social recognition and
increases in anxiety-like and depressive-like behaviors [7,206,216,223]. Neonatal fluoxetine did not
affect adult hippocampal neurogenesis but normalized decreased hippocampal neurogenesis evident
in prenatally restraint-stress adolescent offspring [162,213]. Reduced adult hippocampal neurogenesis
in males from pregestationally stressed dams was not normalized by perinatal fluoxetine. Moreover,
females from this study showed no changes due to maternal stress but did show increased adult
hippocampal neurogenesis as a consequence of the perinatal fluoxetine exposure [160]. Another
study showed increases in prefrontal-striatal connectivity/synchronization after prenatal exposure
to citalopram. Underlying mechanisms may include a decrease in the complexity of prefrontal
neurons (i.e., fewer/shorter branches and reduce PSD-95), supposedly via 5-HT3-regulated increases in
reelin [7,160,216,238]. Of note, other studies have reported an increased synaptic plasticity [150,206].
Another mechanism suggested is the disturbed mPFC excitation/inhibition as determined by a
downregulation in NMDAR1 and CaMKIIα expression and an increase in GABAergic interneurons in
the mPFC. The changes related to the mPFC excitation/inhibition might again be a compensation for
the overall increased prefrontal excitation [223,238]. In support, prenatal fluoxetine exposure caused
augmented spontaneous inhibitory synaptic transmission onto the layer 5 pyramidal neurons within
the mPFC and led to an increase in the migratory speed of inhibitory cortical interneurons [239]. This
is probably due to an upregulation in the 5-HT2A receptor signaling or may be related to a reduced
expression of the transcription factor Npas4 [223,240]. Interestingly, alterations in the pyramidal neuron
excitability seem to depend on the location. That is, an increased excitability was found in the prelimbic
cortex, while in the infralimbic cortex a decreased excitability was found [7]. Adult male offspring
neonatally exposed to fluoxetine showed an increase in the density of hippocampal immature neurons.
In adult female offspring a decreased density was found [213]. Moreover, perinatal fluoxetine exposure
resulted in decreased perineuronal net formation at postnatal day 17 (ongoing critical period [7]) and
24 (critical period closed [7]) in offspring’s hippocampus and basolateral amygdala [241]. Given that
perineuronal nets increase with the maturation of neurons, the latter finding suggests that prenatal SSRI
exposure delays the onset and the closure of a critical period in the development of the hippocampus
and amygdala. Lastly, pregestational fluoxetine exposure affected 5-HT2C receptor gene expression
and editing in neonatal amygdala and PFC. Maternal restraint stress prior to pregestational fluoxetine
administration revealed that fluoxetine exposure can either reverse or enhance 5-HT2C receptor editing
in the neonatal PFC [232].
3.5. Maternal Immune Activation Affects the Tryptophan Pathway and Neurodevelopment of Offspring
Recent reviews have proposed a role for maternal immune activation in the aetiology of ADHD,
ASD, and depression and suggest a potential mediating role for the 5-HT system [242,243]. Immune
activation during pregnancy occurs either upon a viral or a bacterial infection, or when there is a
condition such as pre-eclampsia [244]. Pre-eclampsia is a complex multisystem disorder unique to the
second half of pregnancy and marked by low platelet 5-HT levels [245]. Pre-eclampsia has been shown
to play an important role in the development of neuropsychiatric disorders such as ASD [246–248]. In
the following sections, we describe the effects of induced maternal immune activation on 5-HT-ergic
brain development of the offspring of rodents. In short, maternal immune activation causes a decrease
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in an offspring’s brain 5-HT levels throughout life, independent of the method used and gestational
period studied. During the embryonic period an acute increase in brain 5-HT levels may occur. The
tryptophan and 5-HT-related brain areas that seem to be affected by maternal immune activation are
located in the thalamocortical and the prefrontal-limbic circuits.
3.5.1. Activation of the Fetal Immune System Influences Animal Offspring
Experimentally, the consequences of maternal immune activation in fetal brain development
are often studied in rodents using the immune stimulant polyriboinosinic–polyribocytidylic acid
(Poly(I:C)), an endotoxin injection (Escherichia coli injection) or a flu exposure (influenza administration).
Poly(I:C) affects maternal cytokine signaling, including interleukins (IL) such as IL-6. Since IL-6
seems to be able to pass the placenta, it might be able to affect fetal brain development [249,250]. It is
noteworthy that not all studies found evidence of IL-6 placental–fetal transport [251]. IL-6 is able to
trigger fetal inflammatory processes both directly via placental transfer and indirectly via placental
inflammation [252]. This, in turn, can have widespread effects on brain development, including a
decrease in the survival rate of fetal rostral raphe 5-HT neurons [253].
3.5.2. Changes in Placenta-Derived 5-HT Levels Influence the Animal Offspring
Besides cytokine-induced fetal 5-HT system alterations, maternal immune activation may also
result in other 5-HT system alterations in either the mother or the placenta thereby affecting the
offspring’s (neuro)development. A recent mouse study showed that even though Poly(I:C)-induced
maternal immune activation was associated with a transient IL-6 increase in the maternal serum,
there was no evidence of cytokine accumulation in the fetal brain [254]. Early-gestation poly(I:C)
exposure evoked a transient increase in placental tryptophan levels and TPH1 gene expression and an
increase in enzymatic activity. Placental MAOA gene expression was not affected [254]. Interestingly,
when inducing maternal immune activation at mid- or late-gestation, the development of 5-HT-ergic
neurons in the fetal hindbrain was not influenced [254,255]. This lack of effect is most likely because
the hindbrain is not dependent anymore on placenta-derived 5-HT after E10.5. In contrast, E15–E17
endotoxin exposure did decrease dorsal raphe TPH2 neurons numbers and size when the offspring
was investigated in adulthood [256].
A few studies investigated the effect of maternal immune activation on the fetal brain 5-HT system
but obtained ambiguous results. Early-gestation-induced maternal immune activation increased 5-HT
fetal forebrain levels, increased 5-HT-ergic neurons in the hindbrain, and changed forebrain circuitry
formation (i.e., a reduction in 5-HT axon outgrowth into the forebrain) [254,257]. Late-gestation
endotoxin injection in rats did not affect fetal cortical 5-HT levels but decreased fetal brain TPH1
gene expression [256]. Importantly, human intrauterine bacterial infection, as well as rodent-induced
maternal immune activation, increased the placental kynurenine/tryptophan ratio [254,258,259].
In addition, the fetal rodent brain levels of kynurenine and its metabolites, quinolinic acid and
kynurenine acid, were increased [254,258]. Thus, maternal inflammation may shunt placental
tryptophan metabolism away from 5-HT to the kynurenine pathway.
3.5.3. Maternal Immune System Activation Influences Brain Circuits and Behavior in Animal Offspring
Multiple studies investigated the lasting effects of maternal immune activation on an offspring’s
brain 5-HT system. Together, these studies show that, regardless of the gestational period, induction
method, and animal’s age and species, maternal immune activation decreases 5-HT levels in
the offspring (blood serum [260]; cerebellum [261,262]; frontal and parietal cortices, and the
hippocampus [255–257,263]). This change was accompanied by a decrease in whole brain TPH2
and 5-HTT gene expression and an increase in the gene expression of TPH1 [256]. Early-gestation
poly(I:C) did not affect 5-HT levels in the PFC, amygdala, ventral tegmental area, and the substantia
nigra pars compacta [257,263]. Interestingly, while total striatal 5-HT levels were unaffected [257],
subdividing the area showed a reduction in 5-HT and 5-HIAA levels in the nucleus accumbens but not
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in the caudate putamen [263]. On the contrary, poly(I:C) exposure at E15 decreased 5-HT and 5-HIAA
levels in the caudate putamen but not in the nucleus accumbens of adolescent and adult offspring [264].
Beside the discussed decreases in an offspring’s brain 5-HT levels, these studies also reported
changes in brain and behavior. Late-gestation maternal immune activation can lead to excitotoxic
injury, such as increased apoptosis in the ventrobasal thalamus and a disrupted thalamocortical
development in newborn pups (i.e., a decrease in 5-HT-mediated thalamocortical fibers and a
decrease in 5-HTT expression in the somatosensory cortex) [255]. Early- to mid-gestation maternal
immune activation-induced decreases in an offspring’s brain 5-HT levels were paralleled by sensory
abnormalities and a reduced social contact [260,264]. Additionally, male offspring showed increased
locomotor and stereotypic behaviors. As suggested by the author, these findings might be indicative
of the development of ASD-like behaviors [260]. Both early- and late-gestational activation of the
maternal immune system causes decreases in an offspring’s brain 5-HT levels and results in anxiety-like
behavior [256,260]. Offspring gestationally exposed to poly(I:C) stimulation, specifically during
mid-gestation, showed an increase in depressive-like behaviors together with increased hippocampal
5-HTT levels [265].
4. Discussion
4.1. Gestational Factors Influence Placenta-Derived and Raphe-Nuclei-Produced 5-HT Content
In the main body of this review, in Section 3, we described how five gestational factors affect
the 5-HT system, the brain development, and the behavior in the offspring. In short, all reviewed
gestational factors influence the 5-HT systems, by either increasing or decreasing 5-HT levels in the
mother, the placenta and in the fetus, resulting in a risk of neuropsychiatric disorders in the offspring.
In this Section, 4.1, we summarize the main findings related to the gestational factor influences on an
offspring’s 5-HT system, and we discuss potential underlying mechanisms (Table 4). Subsequently, in
Section 4.2, we discuss how the interaction between gestational factors might amplify or counteract
each other’s impact on the fetal serotonergic system. Next, we summarize and discuss in Section 4.3
the main findings related to the gestational-factor-induced 5-HT-ergic alterations of the structure and
function of the thalamocortical areas, the prefrontal-limbic areas, and the HPA axis. Lastly, in Section 4.4,
we report the main findings related to the gestational-factor-induced risk of neuropsychiatric disorders,
and we discuss the potency of 5-HT-ergic dependent alterations as underlying mechanisms within the
mentioned circuits.
The influence of maternal 5-HT-ergic genotype depends on the gene investigated and whether the
gene variance involves a loss- or gain-of-function mutation. Maternal genotype might influence the
fetal 5-HT system through a variety of mechanisms altering the placenta-derived 5-HT content. The
genotype of the mother may influence maternal gastrointestinal tract function [266] or its responsivity
to gut bacteria (i.e., microbiome [267]). Importantly, the gastrointestinal tract and microbiome, in
turn, influence maternal blood tryptophan and platelet 5-HT levels [267,268]. Consequently, changes
in maternal tryptophan or 5-HT levels potentially alter 5-HT uptake into, and transfer through, the
placenta. Maternal genotype may affect placental 5-HT synthesis (in cases of TPH1 and/or TPH2
polymorphisms) and placental immune- and metabolic-related activations (in case of maternal 5-HTT
availability [6]). In turn, affecting placental 5-HT homeostasis. As maternal risk alleles can be
transferred to the offspring, maternal genotype is also able to influence offspring’s 5-HT system directly
(i.e., 5-HT production, availability, and receptor activity).
Regarding 5-HT-related maternal diet, tryptophan-deprived diets, high-fat diets, and alcohol
consumption seem to mainly reduce an offspring’s 5-HT levels. Instead, high-tryptophan intake and
protein-restricted carbohydrate-enhanced diets seem to be associated with increased 5-HT levels in
offspring. Importantly, for some of the diets, the direction of change seems to differ depending on the
time measured (embryonic vs. throughout life). Longitudinal studies are highly advised to investigate
this research question. Potential mechanisms underlying maternal diets that are specific for tryptophan
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alterations and protein-restricted carbohydrate enhancements are changes in maternal tryptophan and
5-HT levels and their placental uptake and, consequently, the transfer to the fetus. The maternal alcohol
consumption-induced reduction in fetal brain 5-HT levels might be a consequence of alterations within
the intestinal microbiota composition and their function [269,270]. In turn, as shown for the maternal
genotype, these alterations can influence maternal blood tryptophan and platelet 5-HT levels [267,268].
A similar mechanism can be suggested for the maternal high-fat diet-induced changes in offspring
brain 5-HT levels [271,272].
Maternal stress increased fetal brain 5-HT levels in the few studies investigating the 5-HT levels
during the embryonic period. After birth, both increased and decreased 5-HT levels have been reported
after maternal stress. Although there are many differences between maternal stress models, even
studies with similar models, time-windows gender, or ages find opposing effects of maternal stress
on the offspring’s 5-HT system (e.g., regarding 5-HT levels and the expression of TPH2 and 5-HTT;
Table S2). This suggest that these contradicting results in 5-HT levels after birth are due to complex
underlying mechanisms. We would like to highlight the maternal stress-induced decrease in the
expression of Lmx1b, a transcription factor essential for central 5-HT neurons differentiation and
maintenance in the fetal hindbrain and adult raphe nuclei [164]. The decrease in this transcription
factor could potentially lead to decrements in the raphe 5-HT system development and subsequently
diminished brain 5-HT production. Increases in offspring’s brain 5-HT levels are hypothesized to
be related to alterations in placenta-derived 5-HT. Increased maternal tryptophan might either be
transported directly to the fetus or may increase maternal or placental 5-HT levels [142]. Alterations
in the developing raphe nuclei system and the transient 5-HTT expression might be a compensatory
mechanism of increased placenta-derived 5-HT content.
It is generally believed that maternal SSRI intake increases fetal 5-HT levels (see review [273]).
Many of the behavioral and mechanistic neurodevelopmental effects of gestational SSRI exposure
resemble those observed in rodents lacking the 5-HTT [29,239,240,274–276]. Since 5-HTT knockout
in rodents is associated with increased extracellular levels of 5-HT [277], it can be speculated that
gestational SSRI exposure also increases fetal 5-HT levels. However, the few studies that investigated the
actual 5-HT levels of the offspring are inconsistent and cannot be explained by the use of different types
of SSRIs nor by differences in exposure periods. Interestingly, studies investigating both gestational
stress and SSRI exposure mainly show that SSRI exposure normalizes the prenatal stress-induced effects
on offspring’s 5-HT levels, irrespective of whether prenatal stress increases or decreases 5-HT levels in
the offspring (Table S2). Maternal 5-HT-ergic medication intake can influence the fetal 5-HT system
through multiple mechanisms. First, medication decreases maternal platelet 5-HT levels [278,279],
which potentially decrease 5-HT placental transfer. In addition, since maternal blood platelets and the
placenta both express 5-HTT [280,281], medication such as SSRIs may affect placental function as well
as 5-HT transfer. Moreover, most 5-HT-ergic medications are able to pass through the placenta, thereby
creating the possibility to bind to the fetal 5-HTT and influence the offspring’s brain 5-HT receptor
expression [282,283].
Maternal immune activation decreases the offspring 5-HT levels after birth, independent of the
method used and gestational period induced. However, measurements during fetal development are
ambiguous and may suggest a temporal increase in 5-HT levels. Placenta-derived cytokines are able to
activate fetal inflammation, which might affect 5-HT-positive cell survival in the raphe nuclei. High
maternal IL-6 has been suggested to increase placental A/L system amino acid transport [284] and,
thus, potentially increases placental tryptophan transfer and thereby also fetal brain 5-HT levels. On
the contrary, a decrease in placenta-derived 5-HT levels may be because pro-inflammatory cytokines
in the maternal blood activate IDO and TDO, which in turn, trigger the production of kynurenine.
In this way maternal inflammation may shunt placental tryptophan metabolism away from 5-HT to
the kynurenine pathway. In support, maternal immune activation increased IDO expression in the
placenta and in the fetal periventricular region together with an intense microglial activation within
the fetal periventricular region [254,258].
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Table 4. Gestational factors influence multiple 5-HT-ergic systems. When the association between
the gestational factor and the 5-HT system is proven by scientific studies, we report ‘YES’. When the
association is theorized but not yet proven, we report ‘?’. When the association is not investigated, we
report ‘Not Determined’ (N.D.).
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N.D. YES ? YES YES
5-HT: serotonin; 5-HTT: serotonin transporter.
4.2. Synergistic Impact on 5-HT-ergic Systems and Fetal Neurodevelopment
As shown in Figure 2, the discussed gestational factors do not only independently affect the 5-HT
system, and thereby the brain development of the offspring, but also in interaction. As discussed in
Section 3.2.2, high-fat diets leading to obesity during pregnancy increase the risk of maternal and
placental immune activation through increased release of pro-inflammatory cytokines [117,120] but
also the risk of pre-eclampsia via reduced placental vascularity and blood flow leading to a restriction
in placental nutrient delivery [284,285]. Similarly, maternal stress provokes an increase in maternal
immune activation, as shown by human plasma and mice placental IL-6 increments [286,287]. Thus,
although some interactions between maternal factors might result in logical consequences on the
developing 5-HT system, other effects of maternal factor interactions are not that natural and need
more investigation in future studies.
As described in Sections 3.3–3.5, the three gestational factors of maternal depression, maternal
SSRI intake, and pre-eclampsia can alter placental and fetal 5-HT levels and increase risk of ASD.
These factors may interact, given that in humans prenatal antidepressant intake by depressed pregnant
women increases the risk of pre-eclampsia [288–290]. Interestingly, this risk increases when SSRI
treatment continue in the second trimester [288,291]. Of note, another study was unable to replicate
these findings [292]. Importantly, a combined exposure of these three gestational factors may amplify
their actions on the maternal and fetal 5-HT system and might increase the risk of the development of
ASD in the offspring. The synergistic effect of prenatal SSRI intake and pre-eclampsia can be explained
by SSRI-induced increases in placental 5-HT2A receptor activity [26]. As the 5-HT2A receptor is a
key regulator of placentation (influencing placental growth and function), it is suggested to play a
role in the pathophysiology of pre-eclampsia [293,294], thereby influencing the maternal immune
system activity. However, the association between pre-eclampsia and 5-HT2A receptor function was
not supported in another study [295]. Moreover, it is hypothesized that factors including maternal diet
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and genetics can influence the 5-HT2A receptor promoter [296]. Hence, maternal diet and genetics
might influence the synergistic effect of prenatal antidepressant intake and pre-eclampsia.
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Gestational factors do not only independently affect the embryonic brain 5-HT system but are also able
to interact and thereby amplify or counteract each other’s impact on the embryonic brain 5-HT system.
Maternal genotype is abl to influ nce the effects of maternal diet composition, stress, and medication
intake. The maternal immune system is activated by bacteria, viruses, and pre-eclampsia (blue ot)
and is influenced by maternal stress and diet composition. Furthermore, the risk of pre-ecla psia is
influenced by maternal medication intake and diet composition. Gestational factor influences on the
embryonic brain 5-HT system are a consequence of changes in placenta-derived (maternal blood or
placenta) and/or offspring’s raphe-produced (hindbrain) 5-HT content. Factors can influence maternal
tryptophan levels, which influence tryptophan transfer to the embryo and placental 5-HT synthesis
(green arrows). In turn, placental 5-HT synthesis alterations influence the transfer of 5-HT to the
embryo (yellow arrows). Maternal 5-HT levels can influence placental 5-HT levels and transfer to the
embryo as well (orange arrows). It should be mentioned that the placenta also express MAOA and
the 5-HT2A receptor, which can breakdown the supplied/synthesized 5-HT and affect the placental
structure and function, respectively. Gestational factors can influence the placental 5-HT system by
targeting TPH1/2, MAOA, 5-HTT, and/or the 5-HT2A receptor. Some of these factors also influence
the embryonic brain 5-HT system. These direct effects are evident in the fore- and hindbrain and
include fetal 5-HT-ergic genotype, the placental transfer from 5-HT-ergic medications, activation of the
embryonic immune system, and alterations in the raphe-produced 5-HT content due to maternal stress
(placental CORT transfer) and maternal diet. These factors can influence the maternal and placental
pathway at multiple levels: altering maternal tryptophan and 5-HT levels, placental 5-HT synthesis, or
the placental transfer from tryptophan and 5-HT to the fetus.
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Previous studies have demonstrated that SSRIs have reduced efficacy in humans with low 5-HTT
expression due to an inherited 5-HTTLPR S-allele [297]. As such, carrying the 5-HTTLPR S-allelic
variant could be a factor providing some protection against the unwanted effects of SSRIs on an
offspring’s neurodevelopment. If so, the mother may simultaneously have less benefit from the
treatment, increasing the impact of maternal stress and depression on the fetal development. The
5-HTTLPR has also been suggested to affect stress tolerance. Specifically, 5-HTTLPR-SS mothers of
ASD children reported more stressors and an increased reactivity to these stressors in comparison
to 5-HTTLPR-LL mothers. This suggests that this specific maternal genotype together with prenatal
stress increases offspring’s risk of ASD [298]. In support, mouse studies showed that a combination of
maternal stress and maternal 5-HTT genotype affects epigenetic mechanisms in the embryo resulting in
social deficits but not anxiety-like behavior [299,300]. Moreover, maternal TPH2 functional haplotypes
influence maternal depression during and after pregnancy [301].
Maternal 5-HT-ergic genotype can affect the amount of tryptophan and 5-HT that is released into
the maternal and placental circulation (i.e., altered gastrointestinal tract function or responsivity to the
gut microbiome). In this way, maternal genotype may influence the impact of the other gestational
factors. The described examples of interactions between maternal factors might be altered by the
potential of the maternal diet composition to impact a potential negative effect of other maternal
factors. A protein-rich carbohydrate-low diet potentially decreases the transport of tryptophan, while
a protein-low carbohydrate-high diet seems to increase this transport. As a result, a protein-restricted
carbohydrate-enriched diet or tryptophan-high diet may increase the reduced brain 5-HT levels evident
in offspring exposed to the maternal alcohol consumption (3.2.3) and maternal immune activation (3.5).
Further exploration of this potential approach is needed. It is imperative to keep in mind that both too
low and too high 5-HT levels negatively affect fetal neurodevelopment.
4.3. Gestational Factors Influence Offspring’s Brain Circuits
There seems to be a relationship between maternal, placental, and fetal 5-HT system changes
during neurodevelopmental events and the formation and function of the three considered brain
circuits we have discussed. The thalamocortical circuitry is commonly targeted by (1) the maternal
5-HT-ergic genotype, (2) alcohol consumption, (3) stress resulting in increased offspring’s brain 5-HT
levels, (4) SSRI intake, and 5) late-pregnancy immune activation. While a reduction in fetal 5-HT levels
(maternal 5-HTT genotype, alcohol consumption, prenatal SSRI exposure, and immune activation)
resulted in a loss or a broadening of thalamocortical afferents, an increase in 5-HT fetal levels (maternal
stress & potentially neonatal SSRI intake in healthy dams) resulted in an increase in 5-HT-containing
thalamocortical afferents or fewer branches. Interestingly, these findings may indicate that embryonic
5-HT alterations (prenatal SSRI exposure) result in opposing effects on thalamocortical development in
comparison to the direct effects on an offspring’s 5-HT system seen after neonatal SSRI exposure.
The prefrontal-limbic circuitry contains brain functions, which are also often influenced by gestational
factors. This circuitry is targeted by (1) stress models resulting in reduced offspring’s brain 5-HT levels,
(2) SSRI intake, (3) immune activation, and (4) potentially by all discussed maternal diets. Maternal
diets are associated with the offspring 5-HT system alterations in prefrontal-limbic subareas primarily.
Focusing on hippocampal neurogenesis, it has been shown that maternal stress reduces this process while
maternal SSRI exposure is often reported to increase hippocampal neurogenesis. Maternal SSRI exposure
can, therefore, potentially adjust the maternal stress-evoked effects. However, SSRI-induced changes in
hippocampal neurogenesis seem to differ depending on gender and age. Consequently, in some cases
perinatal SSRI exposure alters hippocampal neurogenesis negatively. Furthermore, structural plasticity was
reduced in offspring when exposed to either tryptophan-deprived diets, maternal stress, or SSRI intake by
healthy dams. Interestingly, both tryptophan-deprived and maternal stress exposures were associated with
decreased 5-HT levels in the offspring’s prefrontal-limbic areas.
The HPA-axis is affected by fetal 5-HT changes via influences from (1) maternal stress resulting in
increased and decreased offspring’s brain 5-HT levels, (2) SSRI intake, and (3) potentially by maternal
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5-HT-ergic genotype, protein-restricted carbohydrate-enhanced diets, and alcohol consumption. Maternal
genotype and diets may affect the HPA-axis via influencing 5-HT-ergic receptor expressions. Maternal stress
and SSRI intake have a more widespread effect by altering not only receptor expression but also by altering
the negative feedback loop through, amongst others, corticosterone/cortisol levels and glucocorticoid
receptors in the hippocampus. Maternal stress, regardless of the direction of altered brain 5-HT levels, seems
to cause a hyper-reactive HPA-axis. On the other hand, most studies concerning perinatal SSRI exposure
(human, healthy, and perinatally stressed animal studies) indicate a decrease in HPA-axis reactivity, thereby
normalizing the maternal stress evoked effects. Importantly, perinatal SSRI exposure also impacts the
HPA-axis without normalizing maternal stress (e.g., reducing glucocorticoid receptor density in different
brain areas).
4.4. Gestational Factors Can Influence the Risk to Develop Neuropsychiatric Disorders
Gestational-factor-evoked alterations in the offspring’s brain 5-HT system seem to correlate with an
increased risk in the onset of certain neuropsychiatric disorders (Figure 3). For instance, maternal TPH1
loss-of-function mutations have been associated with an increased risk of developing ADHD. As maternal
TPH1 mutations alter embryonic cell proliferation rate and cause abnormalities in the development of
embryonic cortical regions, these alterations may underlie the increased risk of ADHD. It can be speculated
that these effects are caused by diminished fetal brain 5-HT levels, as TPH1 mutations probably result
in lower maternal platelet and placenta 5-HT levels and, thus, a diminished exogenous 5-HT content.
Furthermore, attentional problems were seen when exposed to Triptans, a 5-HT1B/1D receptor agonist.
Indeed, genetic mutations within these receptors have been associated with the risk of ADHD [302,303].
Regarding ASD, an increased risk was reported in children of 5-HTTLPR-LL-carrying mothers
and in animals exposed to maternal stress or maternal immune activation. Interestingly, enhanced
5-HTT expression seems to result in a decrease in fetal forebrain 5-HT levels and alterations within the
thalamocortical circuitry (5-HTT gain-of-function mutation and prenatal SSRI exposure). These findings
may suggest a potential mechanism through which maternal 5-HTT genotype influences the onset of
ASD. A hyper-reactive HPA-axis and a reduced structural plasticity within the prefrontal-limbic circuit are
suggested as underlying mechanisms after exposure to maternal stress and SSRI intake. Importantly, there
are a few indicators suggesting that maternal SSRI intake after maternal stress restores the stress-induced
changes in the HPA-axis. More elaborated studies are highly advised to investigate this potential further.
Still, both human and animal work concerning SSRI exposure is very inconsistent but overall suggests
a risk of ASD, irrespective of the effects of prenatal stress. This association, however, might change
depending on the environment (e.g., maternal 5-HT-ergic genetic variance affects fetal 5-HT levels, maternal
predisposition to neuropsychiatric disorders, and SSRI efficacy). It would be of importance to take such
environments into consideration as potential interacting factors.
Increased anxiety-like behavior in the offspring is reported after gestational exposure to maternal
genotype, high-fat diets, alcohol consumption, stress, SSRI intake, and immune activation. Research
outcomes may imply that the SSRI-exposure-induced behavior is more related to depressive instead
of anxiety-like behavior. Interestingly, high-fat diets, alcohol consumption as well as maternal
immune activation are proposed to result in decreased 5-HT levels in offspring, which may imply a
relationship between high anxiety levels and gestational-factor-induced decreases in an offspring’s
5-HT levels. Interestingly, these factors (including stress models resulting in reduced offspring’s brain
5-HT levels) are associated with a disrupted structure and function of the prefrontal-limbic circuitry. A
hyper-reactive HPA-axis has been proposed as an underlying mechanism as well.
Maternal immune activation, stress as well as SSRI intake during pregnancy are associated with
an increase in depressive-like behavior in the offspring. Interestingly, thus far only one animal study
investigated prenatal SSRI exposure, rather than perinatal or neonatal exposure, and did not find any
changes in depressive-like behavior [304]. This is consistent with findings from a human study showing
that only late pregnancy SSRI exposure was associated with increased risk of depression [187]. These
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findings suggest that SSRI-induced effects on an offspring’s 5-HT-ergic system are more important
than placental-derived 5-HT content.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 24 of 42 
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Figure 3. Schematic overview of the effects of gestational factors on the offspring’s 5-HT-ergic influence
on brain circuits maturation and the resulting aberrant behavior. Gestational factors (i.e., maternal
5-HT-ergic genotype, 5-HT-related diets, stress exposure, 5-HT-related medication intake, and immune
activation) decrease (arrow blue, left) or increase (arrow red, right) the offspring’s brain 5-HT levels.
The gestational factors in the middle (purple) have been found to increase as well as decrease brain
5-HT levels in the offspring. Gestational-factor-induced alterations in the formation and function of the
prefrontal-limbic circuitry, thalamocortical circuitry, and the HPA-axis are depicted via orange, blue,
and green dots, respectively. We mention which gestational factor has been associated to the highlighted
neuropsychiatric disorders of ASD, ADHD, depression, and anxiety. Furthermore, where possible,
direct links have been depicted between gestational-factor-induced 5-HT-ergic-related changes within
one of the three brain circuits and a neuropsychiatric disorder. 5-HT: serotonin; ASD: autism spectrum
disorders; ADHD: attention deficit hyperactivity disorder; HPA: hypothalamo-pituitary-adrenocortical;
SSRIs: selective serotonin reuptake inhibitor.
5. Conclusions
Addressing both human and animal studies, we show that all gestational factors considered in
the present review (maternal 5-HT-ergic genotype, 5-HT-related diet composition, stress, 5-HT-related
medication, and immune activation) affect both placenta-derived 5-HT and an offspring’s 5-HT
production and availability. Due to these 5-HT changes, all discussed gestational factors are able to alter
thalamocortical and/or prefrontal-limbic circuits and/or the HPA-axis and alter neuropsychiatry-related
behaviors. Therefore, 5-HT changes induced by gestational factors may provide a risk of the onset of
disorders like ASD, ADHD, anxiety, and depression. To date, research does not provide an answer
to which extent placenta-derived 5-HT changes and direct changes to an offspring’s 5-HT system
are causing the offspring’s brain and behavioral changes. Studies comparing first (placenta-derived
5-HT content) versus third trimester of pregnancy (offspring’s brain 5-HT production) can be helpful.
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SSRI-induced normalizations of abnormalities within the prefrontal-limbic and thalamocortical circuits
evident in prenatally stressed offspring might be related to contrasting effects of SSRIs and prenatal
stress on brain 5-HT levels in the offspring. Thereby, illustrating the potential of SSRIs to be a plasticity
factor (suggested in the review [305]). Inconsistencies to whether gestational SSRI exposure influences
ASD, anxiety, and depression still exist, which may imply the influence of other gestational factors. We
argue that beyond the understanding of how a single gestational factor affects brain development and
behavior in the offspring, it is also critical to elucidate the consequences of interacting factors. Hence,
we want to advocate to take gestational factors into consideration when performing human cohort
studies to reveal risk factors for neuropsychiatric disorders. Concerning animal studies, we want
to emphasize the importance to study the potential effect of combining different gestational factors.
Indeed, there seems to be a shift towards research investigating maternal SSRI intake in combination
with prenatal stress. Studying the combined effects of multiple factors creates the opportunity to
examine, for example, whether protein-reduced carbohydrate-enriched maternal diets can reverse a
reduced fetal brain 5-HT content due to a genetic mutation. Furthermore, developing and optimizing
current methodologies, such as whole-genome mapping, may initiate opportunities to examine the
contributions of maternal genotype effects beyond the transmission of risk alleles [306,307]. Such
efforts can create the possibility to disentangle the underlying mechanisms of an increased risk of
neuropsychiatric disorders in children who, for instance, had been exposed to SSRIs during their
development. In conclusion, an enhanced understanding of the interacting gestational factors, and on
which brain circuits they act, will increase our abilities to prevent pregnancies with disadvantageous
consequences for the offspring.
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